ABSTRACT
INTRODUCTION
The amount of specific mRNAs within cells and tissues is important in the regulation of protein synthesis and is commonly used to study the expression of genes in various physiological and pathological processes. Several methods are commonly used to measure the levels of specific mRNAs, including northern blotting, primer extension, nuclease protection and reverse transcription-polymerase chain reaction (RT-PCR). As currently used, none of these methods permit absolute quantitation of mRNAs (i.e., they do not allow determination of the number of specific mRNA molecules in a particular cell culture or tissue sample). Relative levels of an mRNA are usually obtained by assaying the mRNA by one of the above-mentioned methods and normalizing the data against an internal standard RNA, usually ribosomal RNA or the mRNA of a "housekeeping" gene, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Even these relative levels rely on the internal standard RNA being expressed at a constant level in all tissues being examined. This can be an erroneous assumption, because even the expression of housekeeping genes are subject to cellcycle and environmental regulation (5, 9) . Moreover, the validity of the relative levels relies on RNA extraction yields being constant between samples, an assumption that is rarely, if ever, verified. However, it would seem unlikely that the RNA yields from tissues with physical and biochemical differences would be identical.
In this paper, we describe a method based on competitive PCR (2, 6, 11, 14) for the absolute quantitation of specific mRNAs that overcomes these problems. We call this method, "comparative PCR", as actual competition between the target and competitor templates does not occur. It uses nonlimiting amplification conditions and a synthetic external standard RNA to take into account inefficiencies in RNA yield and cDNA synthesis. This method has been used to quantitate the mRNAs of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in a mammary tumor.
MATERIALS AND METHODS

Synthetic External Standard RNA
To prepare the synthetic external standard RNA for quantitative PCR assays, the APL1 plasmid (described below) was linearized with Eco RI and transcribed with SP6 RNA Polymerase (Promega, Madison, WI, USA), according to the manufacturer's instructions. The RNA was electrophoresed in and eluted from 6.5% polyacrylamide/8 M urea gel and ethanol-precipitated. The purified RNA was quantitated by absorbance at 260 nm, re-analyzed electrophoretically to ensure integrity and stored under liquid nitrogen in aliquots until use.
Extraction of RNA
Total RNA was extracted from cultured cells and tumors according to the method of Chomczynski and Sacchi (4), with the following modifications. External standard RNA, transcribed in vitro from the APL1 plasmid, was added to the guanidinium isothiocyanate (GITC) cell lysis solution before lysis at a concentration of 5.25 × 10 -17 mol RNA per million cultured cells or per milligram of tissue. Tumors, kept frozen in dry ice, were pulverized using a mortar and pestle before the addition of cell lysis solution. The purity and quantity of total RNA extracted from samples was determined by spectrophotometric analysis at 260 and 280 nm.
Reverse Transcription
RT of mRNA was performed using 25 µ g total RNA in a 100-µ L reaction volume containing 100 U reverse transcriptase from the avian myeloblastosis virus (AMV) (Molecular Genetic Resources, Tampa, FL, USA), 1 mM deoxynucleotide triphosphates (Amersham Pharmacia Biotech, Castle Hill, NSW, Australia), 1.5 pg of 18-mer oligo(dT) and 100 U RNasin ® Ribonuclease Inhibitor (Promega) in a buffer of 50 mM Tris-HCl, 8 mM MgCl 2 , 30 mM KCl and 1 mM dithioerythritol, pH 8.5 (Boehringer Mannheim, Castle Hill, NSW, Australia). The reaction was carried out for 1 h at 42°C followed by 5 min at 98°C to inactivate the reverse transcriptase. The cDNA was subsequently stored at -70°C until assayed. The sequences of the forward (F) and reverse (R) primers used for comparative PCR assays and the sizes of the products that they generate from cDNA target (T) and competitor (C) templates are shown. Comparative PCR assays were performed on three independent samples of known concentration of plasmid DNA or, for GAPDH, purified PCR product, containing the wild-type target sequences. The average discrepancy between the measured value and the actual value was determined as the correction factor. These values were used to correct the measurement of absolute numbers of mRNA copies in a BC1 tumor sample, determined by comparative PCR using the synthetic external standard RNA, as described in the text. . For phosphorescent imagery, the gels were dried, exposed to a phosphorescent screen overnight, imaged on a BAS1000 Phosphorescent Imager and quantitated with TINA software (both from Fuji, Tokyo, Japan). For fluorescent imagery, gels were stained for 30 min in SYBR ® Green I (Molecular Probes, Eugene, OR, USA) or Vistra Green ™ (Amersham Pharmacia Biotech), according to the manufacturers' instructions, imaged on a 312-nm UV light box with a charged-coupled device (CCD) camera and quantitated with Phoretix (both from UVP, Upland, CA, USA) or TINA software. In calculating the cDNA dilution at which target and competitor products were equivalent, differences in deoxycytosine content (for phosphorescent imaging) or total length (for fluorescent imaging) were taken into account. A molar factor of two was also included, to account for the fact that cDNA is single-stranded, whereas the competitor plasmids are double-stranded and therefore offer twice as many PCR templates.
Comparative PCR
Sequencing
Polyacrylamide gel-purified PCR products were sequenced directly using the Dye Terminator Cycle Sequencing Ready Reaction kit and a Model 373A Fluorescent Sequencer (both from PE Biosystems), according to the manufacturer's instructions.
Plasmids
APL1, the wild-type plasmid used for synthesis of the external standard RNA, was made by insertion of 539 bp of multiple synthetic oligonucleotides, including the sequences for PCR amplification of BCR-ABL, between the Sal I and Sac I sites of pSP64polyA (Promega). The competitor plasmids for this and other targets were made by insertion or deletion of DNA sequences between primer sites, using restriction enzymes or by deletions introduced by PCR primers (3) ( Table 1 ). Complete sequences of the competitor plasmids are available upon request. Plasmids were purified by centrifugation through two cesium-chloride gradients.
Cell Culture and Tumors
The BC1 rat mammary carcinoma cell line was cultured under continuously serum-free conditions as described (8, 12) . Basal media and other culture chemicals were obtained from Sigma (St. Louis, MO, USA). Tumors were induced in 7-week-old syngeneic rats by injection of 0.5 × 10 6 cells in 50 µ L of phosphate-buffered saline (PBS) into the right footpad and allowed to grow for 40 days.
RESULTS
Design of PCR Assays for Quantitating mRNAs
As part of an ongoing investigation into the regulation of extracellular matrix (ECM) destruction by tumors, it was necessary to quantitate MMP and TIMP mRNAs in the BC1 rat mammary carcinoma cell line and in tumors derived from it. To do this, a comparative PCR assay was designed that overcomes many of the problems associated with other mRNA assays. In particular, this protocol permits absolute quantitation of mRNA species, which eliminates the need to base measurements of the levels of the mRNA of interest on comparisons with those of other mRNAs, which may themselves be subject to modulation. In designing comparative PCR assays for the rat MMPs and TIMPs, the opportunity was taken to make methodological choices and innovations that would eliminate several deficiencies in existing quantitative
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Vol. 27, No. 1 (1999) Figure 1 . Specificity of PCRs for target and competitor templates. Silver-stained polyacrylamide gel electrophoretograms of target and competitor PCR products for each target mRNA, amplified under optimized conditions, are shown. All target products were amplified from BC1 cDNA except for the synthetic RNA standard, which was amplified from plasmid DNA. Competitor PCR products were amplified from the respective competitor plasmids. Lanes 2, 4, 6, 8, 10, 12, 14 and 16 show the specific target (T) products for the synthetic RNA standard (APL1), GAPDH, collagenase-3 (Col3), gelatinase B (GelB), stromelysin-1 (Str1), stromelysin-2 (Str2), TIMP-1 and TIMP-2, respectively. The corresponding competitor PCR products (C) for each are shown in the adjacent lanes (i.e., lanes 3, 5, 7, 9, 11, 13, 15 and 17, respectively the samples at the dilution at which equivalent amounts of target and competitor products were generated; ( iii ) to choose PCR conditions such that reactions at the point of equivalence were maintained in the exponential phase of amplification throughout the reaction; and ( iv ) to use a cDNA of known concentration to determine the degree to which amplification bias of target over competitor or vice versa affected the determination of the point of equivalence. The result was a sensitive method that allowed the determination of absolute numbers of copies of MMP and TIMP mRNAs in cell cultures and tissue samples. For the sake of convenience, standard thermal cycling parameters were chosen, so that assays for several mRNAs could be performed simultaneously in a single block.
Comparative PCR assays were developed for the quantitation of the mRNAs encoding rat collagenase-3, gelatinase B, stromelysin-1, stromelysin-2, TIMP-1, TIMP-2, GAPDH and the synthetic external standard, APL1. Figure 1 shows the corresponding target and competitor-derived PCR products for each of the MMPs and TIMPs investigated. The specificity of each primer pair was evaluated empirically on BC1 rat mammary carcinomaderived cDNA and competitor templates. Under the optimized PCR conditions utilized, the primer pairs for each MMP and TIMP specifically amplified products of the expected size. Occasionally, bands corresponding to primer dimer formation were visible. However, these did not interfere with quantitation, as assays were performed under conditions in which reagents were not limiting (see Discussion). In addition to correct size, product identities were verified by direct sequencing. All of the MMP and TIMP sequences were identical to those that have been published or submitted to sequence databanks, except for stromelysin-1. GenBank ® Accession No. X02601 reads C-C at bases 623 and 624, whereas BC1-derived stromelysin-1 cDNA reads A-A. This alters the predicted amino acid at codon 189 from threonine in the original sequence to isoleucine. Figure 2A shows a phosphorescent image of a comparative PCR assay, in which the bands corresponding to target (T) and competitor (C) products were generated. In this case, the target was the low-abundance mRNA for TIMP-1. Note that, as the amount of cDNA added to the reaction increased, the intensity of the bands of the competitor product remained constant, until the amount of cDNA increased past the point of equivalence, indicating that reagents were not limiting at the point of equivalence. Figure 2A , lanes 9 and 10, show the competitor-only and cDNA-only controls, respectively, demonstrating the specificity of the reaction and absence of contamination.
In addition to the expected target and competitor products, a third band or doublet of DNA (labeled H in Figure  2A , lanes 1-4) was routinely seen in comparative PCR assays for each MMP and TIMP, in reactions at or near the equivalence point. Although the identity of the third band(s) was unknown, its appearance was not the result of a nonspecific priming event, as it consistently failed to appear in both the competitoronly and the cDNA-only PCR controls (Figure 2A, lanes 9 and 10) . It was hypothesized that this third band might be the result of the formation of heteroduplexes between target and competitor products, because its occurrence was maximal near the equivalence point. To verify this, the DNA constituting the additional band was analyzed in two ways. First, gel-purified material from both homoduplex bands and the putative heteroduplex band ( Figure 3A , lanes 2-4) were denatured by heating to 96°C and then allowed to renature by cooling slowly to room temperature. Under these conditions, a heteroduplex will separate at the higher temperature into single strands. Upon cooling, each target sense strand can re-anneal with antisense strands from either target or competitor products, thereby forming both homoduplexes and heteroduplexes. Similarly, the target antisense strand and both strands of the competitor product will form both homoduplexes and heteroduplexes, upon cooling. Figure 3A, lane 5, shows that bands corresponding in mobility to both heteroduplexes and homoduplexes were formed upon renaturing the putative heteroduplex product, confirming its identity as a heteroduplex. Control samples of target and competitor homoduplexes reannealed to give bands with their original mobilities ( Figure 3A, lanes 6 and  7) . Secondly, gel-purified homoduplex and putative heteroduplex DNAs were electrophoresed under denaturing conditions. A heteroduplex will dissociate into its constituent target and competitor single strands when denatured. Figure 3B shows that the putative heteroduplex dissociates into two clusters of bands (lane 2), with mobilities corresponding to those resulting from the dissociation of the target and competitor products into single strands ( Figure  3B, lanes 3 and 4) .
Phosphorescent imagery and fluorescent imagery were both suitable for the quantitation of the PCR products. Phosphorescent imagery had the advan -
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Vol. 27, No. 1 (1999) tage of its response to signal intensity being linear over several orders of magnitude. The regression coefficients of the lines of best fit of data obtained by phosphorescent imagery were always greater than 0.9, and the slopes were usually between -0.85 and -1.2 ( Figure  2B) . A slope of -1 is predicted for this type of PCR assay (10) . The small deviations from -1 might be due to variations in the measurement of background signal, because a small adjustment of the background level, by adding or subtracting a fixed amount of signal from all values, caused a substantial change in the slope, while causing just a very small change in the Y-intercept value. The use of fluorescent imagery required that care be taken that the image be captured within the linear response range of the CCD camera, which was limited to approximately three orders of magnitude. Under these conditions, the lines of best fit were similar to those obtained by phosphorescent imagery. To ensure that measurements were taken consistently within the linear response range of the CCD camera, the signal strength of the competitor band in the competitor-only lane in each assay was adjusted by changing the aperture setting of the camera to give a fixed signal output corresponding to the middle of the linear response range. Fluorescent imagery had the advantage over phosphorescent imagery of speed, in not having to dry the gels and expose them overnight to an imaging screen, and avoided the expense and hazard of radioactive isotopes. Both imaging methods had equivalent sensitivity under the conditions used.
In comparative PCR, a discrepancy between the measured value and the actual value for an mRNA species might result when there is a difference in amplification efficiency between target and competitor templates (10) . Therefore, the accuracy of each comparative PCR assay was determined by performing comparative PCR with known amounts of purified competitor and target templates, so that the discrepancies between actual and measured values could be accounted for in assays of samples. The discrepancy, or mean fold error, between the measured value and expected value for each target template, was 1-3-fold for the 8 assays (Table 1) . These values were subsequently used to correct the target measurements made on cDNA samples. In this way, the values were adjusted for the amplification bias intrinsic to each assay and also for the incorporation of products into heteroduplexes.
To verify that the mRNA quantitation was independent of the amount of starting material, TIMP-2 mRNA was quantitated in the BC1-E1 clonal cell line (8), starting with 2.5 ×10 6 , 25 × 10 6 and 50 ×10 6 cells. Six samples of each cell number were independently reverse transcribed and amplified and produced values of 102 ± 40, 122 ±28 and 137 ±39 copies/cell, respectively. Thus, the outcome of the assay for a given mRNA and cell type did not differ significantly, regardless of the amount of starting material over at least a 20-fold range, suggesting that any variations in the yield of RNA due to different amounts of starting material had been taken into account by the use of the external standard.
Expression of MMP and TIMP Genes in Mammary Tumors In Vivo
The comparative PCR assay incorporating the external standard was used to determine the absolute quantities of MMP and TIMP mRNAs in a sample of a rat mammary tumor (Table 1) . High levels of mRNAs encoding the MMPs were detected, ranging from 33-210 × 10 6 copies per milligram tissue. Because each milligram of tissue contains approximately 10 6 cells, as determined by the density of packed cultured cells, this corresponds to approximately 33-210 copies per cell. By comparison, the TIMP mRNAs were present at lower levels, and the biologically unrelated GAPDH mRNA was present at 571 × 10 6 copies per milligram tissue. It has been estimated that less than 2% of expressed genes are expressed at greater than 50 mRNA copies per cell (13) . Thus, collagenase-3, stromelysin-1 and gelatinase B can be said to be expressed at high levels in this tumor.
DISCUSSION
We have described a protocol for the quantitation of mRNAs in cell and tissue samples that overcomes deficien -cies in previous methods, which either do not offer absolute quantitation or do not take into account losses of yield during RNA isolation and cDNA synthesis. The current generally acceptable practice for examining RNA levels is to generate a specific signal using a technique (usually northern blotting) and compare it with the corresponding signal from the product of a housekeeping gene, such as GAPDH. This does not allow absolute quantitation of the mRNA of interest and, even for comparisons of relative mRNA levels to be made, assumes a uniform level of expression of the housekeeping gene in the different tissues or treatments of cells being compared. It is perhaps surprising, given its long history of use as a standard by which the expression of other genes are compared, that the gene for GAPDH was isolated only in 1988 (5) and that, in that paper, its expression was demonstrated to be modulated by insulin. Thus, cells that differ in their responsiveness to insulin or that grow in different concentrations of insulin or similar effectors would produce different amounts of GAPDH mRNA, thereby invalidating its use as a gene of invariant expression. Earlier work had demonstrated tissue-specific variations in the levels of GAPDH mRNA (9) . It is likely that other commonly used internal standard genes undergo regulation that is dependent on environmental influences, tissue specificity or cell cycle.
Absolute quantitation of mRNA levels using the current protocol was made possible by the design of an assay that incorporated the following set of attributes: ( i ) the introduction of a synthetic external standard RNA; ( ii ) the titration of target against a constant amount of competitor, rather than vice versa; ( iii ) the use of PCR conditions in which reagents were not limiting and ( iv ) and the verification of the accuracy of the competitor assays, using known amounts of targets. No previous assay has incorporated all of these attributes, which are essential to the accurate quantitation of mRNAs in cell and tissue samples.
The inclusion of the external standard allowed inefficiencies and inconsistencies of RNA extraction and RT to be taken into account, a feature that is essential to absolute quantitation, but which has not been addressed by previous mRNA assays of cell and tissue samples, although it has been used in the semiquantitation of in vitro transcripts (1) . Without the external standard, it is not possible to take into account losses of mRNA during purification and incomplete cDNA synthesis, thereby making absolute quantitation impossible. If variability of mRNA yields occurs between tissues, even relative quantitation is impossible without knowing the extent to which Research Report the variability has occurred. The introduction of the external standard RNA to account for these errors assumes an identical behavior of the external standard and the mRNA being measured. Thus, it is important to ensure that the cell or tissue, from which the RNA is being extracted, is lysed completely and homogeneously in the GITC solution, and that reverse transcriptase, primers and nucleotides are not limiting during cDNA synthesis.
Most published protocols for competitive PCR assays determine the point of equivalence by co-amplifying a constant amount of sample against a titration of competitor (6) . This is an aspect of PCR assays that has not received much attention previously, but is worthy of scrutiny because it has important consequences for the accuracy of the assay. During PCR, reagents become limiting when cycling continues after a certain amount of product has been amplified. When this occurs, the post-exponential phase of PCR is reached, and the bias in amplification efficiency between the target and competitor sequences, brought about by differences in length and sequence composition, becomes more pronounced, so that the amplification of one template is favored over the other (10) . This amplification bias introduces a discrepancy between the actual and measured amounts of target that increases with cycle number. Those PCRs having a higher amount of total template DNA (target + competitor) will reach plateau phase earlier than those having a lower amount of total template DNA. Thus, the amplification bias and resultant discrepancies in measurements will be different for PCRs containing different amounts of total template DNA (10) . Therefore, in PCR assays in which a constant amount of target-containing sample is co-amplified against a titration of competitor, the amount of total template DNA amplified at the point of equivalence will be different for each sample, resulting in different discrepancies between measured and actual values for each sample. Thus, in those assays, different correction factors would be needed for each different concentration of sample.
The above situation can be avoided by co-amplifying a constant amount of competitor against a titration series of sample, as is done in the present protocol. Using this protocol, the amount of total template DNA amplified at the point of equivalence is equal for all samples, regardless of their target cDNA content. Consequently, the discrepancy between actual and measured amounts of target, due to amplification bias, is constant for all samples and can be taken into account, once it has been determined empirically. Also, by restricting the PCR to 25 cycles, the reagents do not become limiting for the amount of competitor chosen (0.1 amol) (Figure 2) . As a result, the bias in amplification efficiency between target and competitor sequences is minimized (10) , and small amounts of nonspecific products do not interfere, because actual competition for reagents does not occur. To this extent, competitive PCR is a misnomer for assays conducted within the exponential phase of amplification. Even greater sensitivity can often be achieved by reducing the amount of competitor to 0.01 amol and increasing the cycle number to 30.
Although the use of gel electrophoresis to distinguish the products of the two templates is somewhat laborintensive, it has the advantage of being able to measure the products of both the target and the competitor templates in each sample. Under conditions in which reagents are not limiting, such as those used in the present protocol, it is necessary to measure both products. PCR assays that detect only one product measure the product of the template that is added in a fixed amount and rely on competition between it and the template being titrated to determine the point of equivalence. Thus, those types of assays must be taken beyond the exponential phase of amplification, since competition requires that reagents become limiting, and consequently, those types of assays must be subject to the potential problems associated with entry to the post-exponential phase, such as increasing amplification biases. By separating the products electrophoretically and measuring them both to determine their ratio, the necessity for entry into plateau phase is avoided. Another advantage of measuring both products is that it diminishes the so-called "tube effect", in which otherwise identical PCRs can generate different amounts of products in different tubes, due to the nonuniformity of heating blocks and tube shapes. Because the ratio of both products is being measured, and the change in amplification efficiency due to the tube effect is likely to affect both templates equally during the exponential phase, the ratio will not be affected. In contrast, if just one product is being measured, errors due to the tube effect will be incorporated into the data.
Verification of the equivalence point is important in establishing the accuracy of any competitive or comparative PCR assay, but is rarely reported. The amplification bias for each pair of target and competitor templates in the assays described here were determined empirically from a comparative PCR assay on a solution containing a known concentration of purified DNA incorporating the target sequence. The known concentration was compared with the measured concentration, and the proportional error gave a measure of the amplification bias over 25 cycles. That the discrepancy was always less than threefold confirmed that the bias for one template over another was small (<5% per cycle) under the conditions chosen. Importantly, irrespective of its size, this error factor can be taken into account in subsequent assays and is essential to ensuring accuracy of quantitation.
Absolute quantitation is important to understanding gene expression, as it will enable comparisons of mRNA levels to be made between different mRNAs within a sample, between different types of cells and tissues, between different time points and between different laboratories. Also, it enables transcription initiation rates to be determined (7) . The use of the comparative PCR procedure described here avoids problems associated with previously described methods and also contributes a greater sensitivity and specificity than non-PCR-based techniques.
